Screener
Royalty Pharma RPRX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
The source filing: Royalty Pharma’s 10-K, filed February 11, 2026. Open the filing →
- Filed
- Feb 11, 2026, 9:04 AM EST
- Fiscal year
- FY2025
- Accession
- 0001802768-26-000003
FAQ
- What is Royalty Pharma's EBITDA?
- Royalty Pharma (RPRX) reported EBITDA of $361.51M in Q4 2024.
- How has Royalty Pharma's EBITDA changed year-over-year?
- Royalty Pharma's EBITDA decreased by 41.0% year-over-year, from $612.9M to $361.51M.
- What is the long-term trend for Royalty Pharma's EBITDA?
- Over 2 years (2021 to 2024), Royalty Pharma's EBITDA has grown at a -5.7% compound annual growth rate (CAGR), from $1.45B to $1.29B.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Royalty Pharma's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude